Hyperbaric Chamber for Fertility: Emerging Research on HBOT & Reproduction

hyperbaric oxygen therapy (HBOT) is being explored as a potential complementary approach to fertility treatment, but the evidence is still in its early stages. A small number of studies suggest that breathing 100% oxygen under pressure may improve blood flow to reproductive organs, support endometrial growth, and reduce oxidative stress. No large-scale clinical trials have confirmed these benefits, and HBOT is not an established fertility treatment. Anyone considering it should do so only in consultation with a reproductive endocrinologist or fertility specialist. Our potential side effects covers this in detail.

A 2025 cohort study found HBOT improved oocyte yield and embryo quality in women with poor ovarian response, suggesting potential as an adjunctive fertility treatment. Randomized trials are still needed before any firm conclusions can be drawn.²

How HBOT May Affect Fertility

Fertility depends on a complex interplay of hormonal signaling, blood flow, tissue health, and cellular function. HBOT delivers 100% oxygen at pressures higher than normal atmospheric levels, which significantly increases the amount of dissolved oxygen in the blood and tissues. Researchers have proposed several mechanisms through which this may influence reproductive outcomes.

Improved Uterine Blood Flow

Adequate blood supply to the uterus is essential for embryo implantation and early pregnancy. HBOT stimulates angiogenesis (the formation of new blood vessels) and has been shown to improve microcirculation in other clinical contexts, such as wound healing. The theory is that enhanced oxygen delivery to the uterine lining may create a more favorable environment for implantation.

While biologically plausible, clinical evidence for HBOT in fertility remains limited to observational studies. The therapy may benefit specific conditions like thin endometrium through improved uterine blood flow, but it is not FDA-approved for fertility indications.¹

Endometrial Receptivity

The endometrium (uterine lining) must reach a certain thickness and quality for successful embryo implantation. Thin endometrium is a recognized cause of implantation failure in IVF cycles. HBOT’s ability to promote tissue repair and growth factor release has led researchers to investigate whether it can improve endometrial thickness and receptivity. Our study on HBOT improving endometrial receptivity breaks this down further.

Ovarian Oxygenation

Oxygen plays a role in follicular development and oocyte (egg) maturation. Some researchers hypothesize that increasing oxygen availability to ovarian tissue may support healthier egg development, though this mechanism remains largely theoretical in humans.

Reduced Oxidative Stress

Oxidative stress, an imbalance between free radicals and the body’s antioxidant defenses, is implicated in both male and female infertility. It can damage eggs, sperm, and reproductive tissue. While it may seem counterintuitive that delivering more oxygen would reduce oxidative stress, HBOT has been shown to upregulate the body’s own antioxidant enzyme systems, potentially offering a net protective effect on reproductive cells.

Sperm Quality

For male fertility, the proposed mechanisms center on improved oxygenation of testicular tissue, reduced oxidative damage to sperm DNA, and potential improvements in sperm motility and morphology. These mechanisms are plausible based on HBOT’s known effects in other tissues, but direct evidence in the context of male fertility is sparse.

Research on HBOT and Female Fertility

The strongest signal in the research comes from studies on women with thin endometrium, a condition that can make IVF implantation difficult or impossible.

Japanese Studies on Thin Endometrium

A series of small studies from Japanese fertility clinics have provided the most cited evidence for HBOT in reproductive medicine. Researchers observed that women with persistently thin endometrium (below 7mm) who underwent HBOT sessions showed measurable increases in endometrial thickness. In some cases, women who had experienced repeated implantation failure were able to achieve pregnancies after incorporating HBOT into their treatment protocol.

One study published by Mitrovic and colleagues examined women whose endometrial lining failed to respond to standard hormonal preparation. After a course of HBOT sessions, a meaningful proportion showed improved endometrial thickness and went on to have successful embryo transfers. The sample sizes were small (typically under 40 patients), there were no randomized control groups, and the results have not been replicated in large, well-designed trials.

IVF Preparation

Some fertility clinics, particularly in Japan and parts of Europe, have begun offering HBOT as an adjunct therapy during IVF preparation. The rationale is that improving uterine blood flow and tissue oxygenation before embryo transfer may increase the chances of implantation. Early case reports are encouraging, but the absence of randomized controlled trials means we cannot separate the effects of HBOT from other variables in these patients’ treatment protocols.

General Reproductive Health

Beyond IVF-specific applications, some practitioners suggest HBOT may benefit women with conditions that affect fertility indirectly, such as chronic pelvic inflammation or poor ovarian response. These claims are largely anecdotal and lack supporting clinical data.

For a broader look at the state of evidence across all conditions, see our comprehensive guide to HBOT research.

Research on HBOT and Male Fertility

Research on HBOT and male fertility is even more limited than the female fertility data, and most of what exists comes from animal studies and small observational reports.

Sperm Quality and Oxidative Stress

Oxidative stress is one of the most common identifiable factors in male infertility, contributing to sperm DNA fragmentation, poor motility, and abnormal morphology. Animal studies have demonstrated that HBOT can reduce oxidative markers in testicular tissue and improve sperm parameters in rodent models. Whether these findings translate to meaningful improvements in human male fertility remains an open question.

Limited Human Data

A small number of case reports and pilot studies have explored HBOT for men with poor semen analysis results. Some reported modest improvements in sperm count, motility, or morphology after a course of HBOT sessions. These studies lacked control groups, were not blinded, and involved very small numbers of participants. No conclusions can be drawn from this evidence alone.

The honest assessment is that HBOT for male fertility is a hypothesis supported by biological plausibility but not yet by clinical evidence.

Treatment Protocols

There is no standardized HBOT protocol for fertility. The protocols used in published studies and clinical practice vary considerably, but some general patterns have emerged. For a detailed breakdown, read our what to expect during treatment.

• Session count: Most protocols involve 10 to 20 sessions, typically completed in the weeks leading up to an IVF cycle or embryo transfer.
• Pressure: Sessions are usually conducted at 1.5 to 2.0 ATA (atmospheres absolute), which is on the lower to moderate end of clinical HBOT pressures.
• Duration: Each session typically lasts 60 to 90 minutes.
• Frequency: Most protocols call for daily or near-daily sessions over a 2- to 4-week period.
• Timing: For women undergoing IVF, sessions are generally scheduled during the follicular phase or during endometrial preparation before a frozen embryo transfer.

If you are new to HBOT and want to understand what sessions involve, our guide to HBOT sessions covers what to expect during HBOT in detail.

These protocols are based on clinical judgment and small studies, not on dose-finding trials or established guidelines. Any fertility-related HBOT protocol should be coordinated between an HBOT provider and a reproductive endocrinologist.

Important Caveats

Transparency matters, especially with a topic as emotionally significant as fertility. Here is what you should know before considering HBOT as part of a fertility plan.

The Evidence Is Very Early

No large randomized controlled trials have been conducted on HBOT for fertility. The existing studies are small, mostly uncontrolled, and concentrated in a few research groups. Promising early results do not equal proven efficacy. The history of reproductive medicine includes many interventions that showed early promise but failed to demonstrate benefit in rigorous trials.

Insurance Does Not Cover It

HBOT for fertility is not an FDA-approved indication, and no HBOT insurance provider covers it for this purpose. You can learn more about coverage specifics in our HBOT insurance coverage guide. Out-of-pocket costs for a 10- to 20-session course can range from $2,000 to $6,000 or more, depending on the facility and location. This is a significant expense on top of already costly fertility treatments.

It Is Not a Standalone Treatment

No credible provider suggests HBOT as a replacement for conventional fertility care. It is being explored strictly as a complementary therapy, something that might improve outcomes when added to an established treatment plan. Anyone marketing HBOT as a primary fertility solution should be viewed with skepticism.

Discuss It With Your Fertility Specialist

Before pursuing HBOT for fertility, have a direct conversation with your reproductive endocrinologist. They can help you weigh the potential benefits against the costs and time commitment, and they can advise on whether your specific situation (such as thin endometrium or recurrent implantation failure) makes you a reasonable candidate for trying this approach. We cover this topic thoroughly in our anti-aging benefits of HBOT.

For context on how long benefits may persist after completing sessions, see our article on how long HBOT effects last.

Who Should Not Try HBOT

HBOT is generally safe when administered by trained professionals, but it is not appropriate for everyone. Discuss your full medical history with your provider before starting treatment.

Absolute Contraindications

HBOT should not be used if you have:

• Untreated pneumothorax (collapsed lung) – pressure changes can worsen this condition and become life-threatening
• Certain chemotherapy drugs – bleomycin, cisplatin, doxorubicin, and disulfiram may interact dangerously with high-oxygen environments

Relative Contraindications

Your provider may need to take extra precautions or postpone treatment if you have:

• Upper respiratory infection or sinus congestion – difficulty equalizing pressure can cause ear or sinus barotrauma
• Seizure disorder – high-pressure oxygen can lower seizure threshold in susceptible individuals
• Chronic obstructive pulmonary disease (COPD) – altered breathing drive may require modified protocols
• High fever – increases the risk of oxygen toxicity
• History of ear surgery or chronic ear problems – pressure equalization may be difficult or risky
• Claustrophobia – may require sedation or use of a multiplace chamber instead
• Pregnancy – insufficient safety data exists for routine use during pregnancy

Talk to Your Doctor First

Even if you do not have the conditions listed above, always consult your physician before starting HBOT, especially if you take insulin (blood sugar may drop during treatment), have a pacemaker or implanted device, or are currently taking any medications. For a full overview of HBOT side effects and risks, see our detailed guide.

References

1. Thin endometrium and HBOT research cited in clinical practice reviews. PubMed
2. 2025 Cohort Study. “Hyperbaric oxygen therapy improves oocyte yield and embryo quality in poor ovarian responders.” Reprod Biol Endocrinol. DOI: 10.1186/s12958-025-01475-z. PMID: 41250167.